Ticagrelor approved for NHS use post-MI

The antiplatelet drug ticagrelor (Brilique) can now be prescribed on the NHS to reduce the risk of atherothrombotic events following MI.

Ticagrelor, in combination with aspirin, has been recommended by NICE as an option for preventing atherothrombotic events in adults who have had an MI and are at high risk of a further event.

Treatment should be stopped when clinically indicated or after a maximum of three years.

NICE already recommends ticagrelor, in combination with low-dose aspirin for up to 12 months, as an option to prevent atherothrombotic events in patients with acute coronary syndromes (ie, STEMI, NSTEMI or unstable angina). 

Ticagrelor targets the P2Y12 adenosine diphosphate (ADP) receptor to prevent ADP-mediated platelet activation and aggregation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more